BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sadrkhanloo M, Entezari M, Orouei S, Ghollasi M, Fathi N, Rezaei S, Hejazi ES, Kakavand A, Saebfar H, Hashemi M, Goharrizi MASB, Salimimoghadam S, Rashidi M, Taheriazam A, Samarghandian S. STAT3-EMT axis in tumors: modulation of cancer metastasis, stemness and therapy response. Pharmacol Res 2022;:106311. [PMID: 35716914 DOI: 10.1016/j.phrs.2022.106311] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Sadrkhanloo M, Paskeh MDA, Hashemi M, Raesi R, Motahhary M, Saghari S, Sharifi L, Bokaie S, Mirzaei S, Entezari M, Aref AR, Salimimoghadam S, Rashidi M, Taheriazam A, Hushmandi K. STAT3 signaling in prostate cancer progression and therapy resistance: An oncogenic pathway with diverse functions. Biomedicine & Pharmacotherapy 2023;158:114168. [DOI: 10.1016/j.biopha.2022.114168] [Reference Citation Analysis]
2 Li Z, Liu Y, Shen S, Shen F, Li W, zhang C, Zeng L. POLR2J is a potential biomarker for abnormal tumor progression, vorinostat sensitization, immune infiltration, and prognosis of glioblastoma multiform.. [DOI: 10.21203/rs.3.rs-2473762/v1] [Reference Citation Analysis]
3 Li J, Li Z, Gao Y, Zhao H, Guo J, Liu Z, Yin C, Zhao X, Yue W. Integrating single-cell RNA sequencing and prognostic model revealed the carcinogenicity and clinical significance of FAM83D in ovarian cancer. Front Oncol 2022;12:1055648. [PMID: 36568230 DOI: 10.3389/fonc.2022.1055648] [Reference Citation Analysis]
4 Gresseau L, Roy ME, Duhamel S, Annabi B. A Signaling Crosstalk Links SNAIL to the 37/67 kDa Laminin-1 Receptor Ribosomal Protein SA and Regulates the Acquisition of a Cancer Stem Cell Molecular Signature in U87 Glioblastoma Neurospheres. Cancers (Basel) 2022;14. [PMID: 36497426 DOI: 10.3390/cancers14235944] [Reference Citation Analysis]
5 Bin Y, Deng W, Hu H, Zeng Q, Chen J, Xu Y, Dai Y, Liao A, Xiao W. RASSF1A inhibits epithelial–mesenchymal transition of gastric cancer cells by downregulating P‐JNK. Cell Biology International 2022. [DOI: 10.1002/cbin.11958] [Reference Citation Analysis]
6 Zhou X, Liu T, Deng S, Zhang T, Wu D, Xu Y. PAMR1 is a favorable diagnostic and prognostic biomarker in hepatocellular carcinoma.. [DOI: 10.21203/rs.3.rs-2114251/v1] [Reference Citation Analysis]
7 Fu Z, Zhu G, Luo C, Chen Z, Dou Z, Chen Y, Zhong C, Su S, Liu F. Matricellular protein tenascin C: Implications in glioma progression, gliomagenesis, and treatment. Front Oncol 2022;12:971462. [DOI: 10.3389/fonc.2022.971462] [Reference Citation Analysis]
8 Hatina J, Kripnerová M, Houfková K, Hajdůšková M, Navvabi N, Havlíčková N, Pešta M. Recent Progress in Urothelial Bladder Carcinoma: Basic Biology, Molecular Characterization, Conventional and Innovative Therapies and Tumour–Stroma Interactions. Interdisciplinary Cancer Research 2022. [DOI: 10.1007/16833_2022_83] [Reference Citation Analysis]